The Global Vaccines Market 2008-2023

March 19, 2009 - PRLog -- Report Details
The period 2008-2023 will see a vaccine “boost”. There will be a new resurgence in the sales and utilisation of vaccines. Are you prepared for this? You should be.

During this period, vaccines will be one of the fastest growing segments of the pharmaceutical market. Vaccine revenues will increase in size by several hundred percent between 2007 and 2023. This brand new in-depth report The Global Vaccines Market, 2008-2023 describes trends in the market both quantitatively and qualitatively. In recent years, this global vaccines market has undergone a renaissance, as the importance of vaccines in both developed and developing nations becomes underlined by epidemiological patterns and healthcare needs.

The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer. Visiongain notes that many healthcare providers are viewing preventative medicine enthusiastically, being aware of the significant increases in quality of life and reduction of healthcare expenditure that can result from prophylaxis. The vaccines industry is responding with innovative products, making full use of technological advances in biotechnology. This market has great developmental potential, both therapeutically and commercially. There are currently more than 1000 vaccines in research and development worldwide.

In particular, The Global Vaccines Market, 2008-2023 concentrates on the following essential aspects of the vaccine industry:
• Sales forecasts for vaccines by disease area, brand and country, including novel therapeutic vaccines
• Examination of strengths, weakness, opportunities and threats facing the vaccine industry
• Expert opinion from key-opinion leaders in the field
• In-depth analysis of the vaccine pipeline
• Analysis of the prospects for therapeutic vaccines
• Geographical breakdown of the vaccine market, including the leading emerging markets of China and India
• Coverage of future trends in vaccine technology, formulation and manufacturing
• Identification of key industrial players in the vaccines market.

The Global Vaccines Market, 2008-2023 examines the vaccines market comprehensively, using unique primary and secondary research. The report includes full transcripts of interview – you cannot get this information anywhere else.

Also included are company reports, filings and industry databases. Exclusively, visiongain have applied their in-house analytical techniques for financial forecasting and analysis of drivers and restraints. Now available to you this comprehensive market-based report with detailed analyses, forecasts and informed opinion is essential to your vaccine market development.

Therapeutic vaccines differ from currently-marketed vaccines. Instead of simply preventing infection from disease, therapeutic vaccines work with the body’s immune system to fight diseases and disorders, including cancer, addiction and allergies. Their therapeutic and commercial potential is vast. Visiongain predicts that therapeutic vaccines will significantly expand the market for vaccines, contributing to rapid revenue growth during the period 2008 to 2023.

Why you should buy this report:
• To receive a comprehensive analysis of the prospects for vaccines, including key metrics and predicted revenues, by vaccine disease area and leading brand
• To receive forecasts of vaccine sales in leading country markets from 2008-2023,  including China and India
• To discover the views of experts in the vaccines sector
• To determine the forces that influence the market for vaccines: drivers, restraints, opportunities and threats
• To find out where the vaccines market is heading - both technologically and commercially from 2008 to 2023.

Companies Listed
Acambis
Accentia Biopharmaceuticals
ACE BioSciences
Advisory Committee on Immunization Practices (ACIP) [US]
Aeras Global TB Vaccine Foundation
ALK-Abelló
Allergy Therapeutics
AnGes MG
Antigenics
Astellas
AstraZeneca
AVANT Immunotherapeutics
Avax Technologies
Barr
Bavarian Nordic
Baxter
Bharat Biotech
Bill & Melinda Gates Foundation
Biogen Idec
Biological E.
Biotecnol
Celtic Pharma
Centers for Disease Control and Prevention (CDC) [US]
China National Biotec Group
Chiron (acquired by Novartis in 2006)
Computer Sciences Corporation (CSC)
Crucell
CSL
Cytos Biotechnology
Daiichi Sankyo
Dendreon
Diamyd Medical
Dynavax
DynPort Vaccine Company (DVC) [subsidiary of Computer Sciences Corporation (CSC)]
Emergent Biosolutions
European Medicines Agency (EMEA)
Food and Drug Administration (FDA)
GAVI Alliance
Genelabs
Genetic Immunity
GenVec
GlaxoSmithKline (GSK)
GlobeImmune
Green Cross [Korea]
Independent Pharmaceutica
Inovio Biomedical
Intercell
International AIDS Vaccine Initiative
Intracel
Kaketsuken
Karolinska Institutet [Sweden]
LipoNova
Lonza
MedImmune (acquired by AstraZeneca in 2007)
Menarini
Merck & Co.
Merck KGaA
Mitsubishi Tanabe
Nabi Biopharmaceuticals
NasVax [Israel]
National Institute of Allergy and Infectious Diseases (NIAID) [US]
Novartis
Novavax
Oncothyreon
Oxford BioMedica
Pan American Health Organization (PAHO)
Petrovax
Pfizer
PharmAthene
Pharmexa
Protein Sciences
Ranbaxy
Roche
Sanofi Pasteur MSD [joint venture between Merck & Co. and Sanofi-Aventis]
Sanofi-Aventis
Schering-Plough
Serum Institute of India
Sinovac
Solvay
Targeted Genetics
Therapeutic Goods Administration [Australia]
Transgene
Tripep
UMN Pharma
UNICEF (United Nations Children's Fund)
University of Queensland [Australia]
US Census Bureau
Vaccine Research Center (VRC) [part of NIAID, US]
Vaccinogen
VaxGen
Vaxine [Australia]
Vical
Virax
Worldwide Health Organization (WHO)
Wyeth
Wistar Institute [US]
Ludwig Institute of Cancer Research
Xenova (acquired by Celtic Pharma in 2005)

Visiongain ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=336
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.